Table 2:

Summary of Adverse Events in the Safety Population^*

Adverse Events	Pertuzumab + TDM1 (n=163)
Number of patients with at least one, n (%)
Grade 1	155 (95.1)
Grade 2	85 (52.1)
Grade ≥ 3 AEs	12 (7.4)
AE leads to Tx discontinuation	2 (1.2)
AE with fatal outcome	0 (0)
Grade ≥ 3 AEs that occurred in ≥ 1% of patients
Diarrhea	3 (1.8)
Hypokalemia	2 (1.2)
Platelet count decreased	2 (1.2)

^*Listed are all AEs regardless of attribution to study drugs with an onset that occurred from the first dose of treatment through the first study visit after breast surgery.

Abbreviations: AE, adverse event; Tx, treatment